Statistics for Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Total visits
| views | |
|---|---|
| Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial | 4 |
Total visits per month
| views | |
|---|---|
| April 2024 | 0 |
| May 2024 | 3 |
| June 2024 | 1 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
File Visits
| views | |
|---|---|
| Boni2022Praluzatamab-CCBYNCND.pdf | 3 |
Top country views
| views | |
|---|---|
| United States | 3 |
| India | 1 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |
| Greenwood | 1 |
| Pune | 1 |